Overview
Bacterial meningitis and septicemia caused by Neisseria meningitidis. Rapidly fatal without treatment; vaccination required for Hajj pilgrims and recommended for Africa's meningitis belt.
Symptoms
Symptoms | Frequency | Severity | Onset |
|---|---|---|---|
| Fever | 90% | Severe | Early |
| High fever | 70% | Severe | Early |
| Irritability | 70% | Moderate | Early |
| Neck stiffness | 75% | Severe | Early |
| Photophobia | 60% | Moderate | Early |
| Severe headache | 85% | Severe | Early |
| Vomiting | 65% | Moderate | Early |
| Chills | 55% | Moderate | Early |
| Fatigue | 50% | Mild | Early |
| Loss of appetite | 55% | Mild | Early |
| Malaise | 50% | Mild | Early |
| Myalgia | 45% | Mild | Early |
| Nausea | 55% | Mild | Early |
| Arthralgia | 25% | Mild | Early |
| Back pain | 20% | Mild | Early |
| Sore throat | 25% | Mild | Early |
| Swollen lymph nodes | 20% | Mild | Early |
| Confusion | 40% | Severe | Peak |
| Petechiae | 65% | Critical | Peak |
| Rash | 70% | Severe | Peak |
| Altered consciousness | 30% | Critical | Peak |
| Bruising | 25% | Severe | Peak |
| Dehydration | 35% | Moderate | Peak |
| Hemorrhage | 15% | Critical | Peak |
| Hypotension | 30% | Critical | Peak |
| Seizures | 20% | Critical | Peak |
| Shock | 12% | Critical | Peak |
| Tachycardia | 60% | Moderate | Peak |
Transmission
Overview
Severe bacterial infection of the membranes surrounding the brain and spinal cord.
Overview
Meningococcal disease is a severe bacterial infection caused by Neisseria meningitidis, a gram-negative diplococcus with 13 serogroups, of which 6 cause nearly all disease: A, B, C, W, X, and Y. Transmission occurs via respiratory droplets and close contact (kissing, shared utensils, crowded living). Asymptomatic nasopharyngeal carriage rate is 5–10% (up to 25% in adolescents). The bacterium can invade the bloodstream causing meningococcemia and/or cross the blood-brain barrier causing meningitis. The disease can progress from first symptoms to death within 24 hours, making it one of the most feared bacterial infections. Case fatality: 10–15% even with optimal treatment; up to 50% in meningococcemia with purpura fulminans.
Emergency Signs
MEDICAL EMERGENCY — seek care IMMEDIATELY (minutes count):
-
Non-blanching petechial or purpuric rash (do the glass test: press a glass tumbler against rash — if spots do NOT fade, call emergency services)
-
Severe headache with neck stiffness and high fever
-
Photophobia (light hurting the eyes) with fever
-
Altered consciousness: confusion, drowsiness, difficult to wake
-
Seizures
-
Cold hands and feet with fever (circulatory compromise)
-
Rapid breathing or difficulty breathing
-
In babies: bulging fontanelle, high-pitched or moaning cry, pale/blotchy skin, refusing to feed, stiff body or floppy/unresponsive
Detailed Symptoms
Most common signs and symptoms
Incubation: 2–10 days (typically 3–4 days). Clinical presentations:
Meningococcal meningitis (most common form, ~50% of cases):
-
Sudden onset severe headache
-
High fever, neck stiffness (nuchal rigidity), photophobia — classic meningeal triad
-
Nausea and vomiting (often projectile)
-
Altered mental status: confusion → drowsiness → coma
-
Kernig sign (inability to extend knee when hip flexed) and Brudzinski sign (neck flexion causes hip/knee flexion)
-
Seizures (20–30%, especially in children)
-
In infants: irritability, bulging fontanelle, poor feeding, high-pitched cry (classic signs may be absent)
Meningococcemia (septicemia — ~40% of cases, may occur with or without meningitis):
-
Rapid onset fever with rigors
-
Petechial/purpuric rash: Initially non-blanching petechiae → coalescing purpura → purpura fulminans (disseminated intravascular coagulation with hemorrhagic necrosis)
-
Glass test: Press a clear glass against the rash — if it does NOT fade, suspect meningococcal septicemia → EMERGENCY
-
Tachycardia, hypotension, cold extremities (circulatory collapse)
-
Multi-organ failure in fulminant cases
-
Limb ischemia (may require amputation in survivors)
Fulminant course: Can progress from first symptom to death in <12–24 hours.
Knowing the symptoms is the first step to a quick response.
Course of Disease
Typical disease course:
- Incubation period: 2–10 days (average 3–4 days).
- Prodromal phase (hours): Upper respiratory symptoms, fever, headache — often indistinguishable from viral illness. Critically, this phase may be very brief.
- Acute meningitis (hours to 1–2 days): High fever, severe headache, neck stiffness, photophobia, vomiting. Kernig and Brudzinski signs. Altered consciousness.
- Meningococcemia (may occur with or without meningitis): Petechial rash → purpura → purpura fulminans. Hypotension, tachycardia, DIC. Can progress from first symptom to death within 12–24 hours.
- Resolution with treatment: Antibiotics (ceftriaxone/cefotaxime) should be given within 1 hour of clinical suspicion. Dexamethasone as adjunct.
Critical feature: Fulminant meningococcal septicemia can progress from apparent good health to death within 12–24 hours. The non-blanching petechial rash is a red-flag sign requiring immediate emergency care.
Diagnosis
How this disease is identified
Meningococcal disease is a medical emergency — do NOT delay treatment for diagnostics.
-
Blood cultures: Obtain BEFORE antibiotics if possible (positive in 40–70%)
-
Lumbar puncture (when safe): CSF shows: elevated WBC (polymorphonuclear predominance), elevated protein, decreased glucose, gram-negative diplococci on Gram stain (60–90% sensitivity) – Contraindicated if: signs of raised ICP, coagulopathy, cardiorespiratory compromise, local skin infection
-
CSF/blood PCR: Most sensitive (>90%); can detect N. meningitidis even after antibiotic administration
-
Latex agglutination: Rapid serogroup identification from CSF
-
Complete blood count: Leukocytosis or leukopenia (poor prognosis if leukopenic); thrombocytopenia; elevated CRP/procalcitonin
-
Coagulation panel: DIC screen (prolonged PT/aPTT, elevated D-dimer, low fibrinogen) — critical in meningococcemia
-
Skin biopsy of petechiae: Can confirm diagnosis even after antibiotics
Critical rule: If meningococcal disease suspected → give parenteral antibiotics IMMEDIATELY, then investigate.
Treatment
Available treatment methods
IMMEDIATE TREATMENT IS LIFE-SAVING. Minutes matter.
Pre-hospital (GP/clinic):
- Intramuscular benzylpenicillin (or ceftriaxone) IMMEDIATELY upon clinical suspicion, before transfer to hospital
Hospital treatment:
-
First-line: Ceftriaxone 2 g IV every 12 hours (or cefotaxime 2 g IV every 4–6 hours) × 7 days
-
Penicillin-susceptible confirmed: Benzylpenicillin IV may be used
-
Adjunctive dexamethasone: 0.15 mg/kg IV every 6 hours × 4 days — give before or with first antibiotic dose; reduces mortality and neurological sequelae in bacterial meningitis (de Gans 2002 NEJM)
Meningococcal septicemia (aggressive resuscitation):
-
Aggressive IV fluid resuscitation (may need 40–60 mL/kg in first hour)
-
Vasopressor support (noradrenaline first-line)
-
Fresh frozen plasma, platelets if DIC present
-
ICU admission; may require ventilation, renal replacement therapy
-
Activated protein C was used historically but no longer recommended
Chemoprophylaxis for close contacts:
-
Ciprofloxacin 500 mg PO single dose (adults) or rifampicin 600 mg BID × 2 days
-
Give to household contacts, kissing contacts, healthcare workers with unprotected direct exposure to secretions
-
Administer within 24 hours of case identification
Most cases are effectively treated with early diagnosis.
Prevention Details
How to protect yourself
Vaccination:
-
Meningococcal ACWY conjugate vaccine (MenACWY — Menveo, Nimenrix, MenQuadfi): Conjugate vaccines provide T-cell dependent immunity (longer lasting than polysaccharide). Single dose; booster every 5 years if ongoing risk. Licensed from age 2 months (varies by product).
-
Meningococcal B vaccine (MenB — Bexsero, Trumenba): Covers serogroup B (common in Europe, Americas). 2-dose schedule. Not combined with ACWY.
-
Meningococcal polysaccharide (MPSV4): Older vaccine; less immunogenic; no longer preferred
-
Pentavalent ACYWX: In development; critical for Africa where serogroup X is emerging
-
MenAfriVac (conjugate A): Single dose; eliminated serogroup A epidemics in Africa's meningitis belt since 2010 (one of the greatest vaccine successes)
Travel-specific requirements:
-
Hajj/Umrah (Saudi Arabia): Meningococcal ACWY vaccination REQUIRED for visa; must be given ≥10 days before arrival
-
Meningitis belt travel (Sahel): MenACWY recommended, especially during dry season (December–June)
-
College students living in dormitories: MenACWY + consider MenB
Outbreak response: WHO threshold: 10 cases/100,000/week for 2 consecutive weeks → mass vaccination campaign.
Preparation is the best protection.
Travel Advice
Risk to travelers:
-
High risk: Sub-Saharan Africa meningitis belt during dry season (December–June); Hajj/Umrah pilgrimage; crowded mass gatherings
-
Moderate risk: Backpackers and youth travelers in shared accommodation (hostels, dormitories)
-
MenACWY vaccine required: Hajj/Umrah visa (Saudi Arabia mandates it)
-
MenACWY vaccine recommended: Travel to meningitis belt, prolonged close contact with local populations, healthcare workers in outbreak settings
-
Carry a meningococcal vaccination certificate when traveling to Saudi Arabia or affected countries
-
Seek immediate medical care for fever + non-blanching rash — this is a life-threatening emergency
-
Serogroup B vaccine additionally recommended for prolonged stays in settings with known serogroup B activity (some European countries)
-
Vaccination does not cover all serogroups — maintain awareness of symptoms regardless
How common is it?
Statistics and geographic data
Global burden: WHO estimates 1.2 million cases and 135,000 deaths annually (2019 pre-COVID). Epidemiology varies by serogroup and region:
-
Africa meningitis belt (26 countries from Senegal to Ethiopia): Historically devastating serogroup A epidemics during dry season (December–June)
-
MenAfriVac introduction (2010) eliminated serogroup A epidemics — now serogroups C, W, and X are emerging
-
Europe/Americas: Serogroups B, C, W, Y predominant
-
outbreaks in universities, military
-
serogroup W increasing
-
Asia: Variable
-
serogroup A (India, China), B, C, W
-
underreported
-
Middle East: Hajj-associated outbreaks historically drove global spread (2000 Hajj W135 epidemic)
-
Age distribution: Bimodal — infants (<1 year: highest incidence) and adolescents/young adults (15–25: high carriage rate)
-
Risk factors: Crowded living (dorms, barracks, Hajj), complement deficiency, asplenia, HIV, active/passive smoking, preceding viral URI
Risk Factors
Who is most at risk
Travel to the African meningitis belt (sub-Saharan Africa), Hajj pilgrimage, living in close quarters (dormitories, military barracks), complement deficiency or asplenia, adolescents and young adults (15–24 years), infants under 1 year, exposure during outbreaks.
Complications Details
Potential complications
Meningococcal disease carries severe morbidity even with optimal treatment:
-
Mortality: 10–15% with treatment
-
up to 50% in fulminant meningococcemia
-
death can occur within hours
-
Limb amputation: Purpura fulminans causes ischemic necrosis of extremities
-
10–20% of survivors require amputation of fingers, toes, or limbs
-
Hearing loss: 5–10% of meningitis survivors
-
may be bilateral and profound
-
cochlear implant may be needed
-
Neurological sequelae (10–20%): Cognitive impairment, seizure disorder, motor deficits, hydrocephalus, cranial nerve palsies
-
Skin scarring: Extensive necrotic skin lesions requiring grafting
-
Adrenal hemorrhage (Waterhouse-Friderichsen syndrome): Bilateral adrenal infarction → acute adrenal insufficiency
-
high mortality
-
Renal failure: From shock, DIC, and myoglobin deposition
-
Psychological impact: PTSD, anxiety, depression in survivors and families
-
Arthritis: Reactive arthritis in 5–10% during convalescence (immune-mediated)
-
Long-term disability: Up to 40% of survivors have at least one residual disability
Recovery & Outlook
Expected outcomes and recovery
With treatment: CFR 8–15% (meningitis), 20–40% (meningococcemia/septicemia).
Without treatment: Nearly 100% fatal.
Sequelae in survivors:
-
Hearing loss: 5–10%.
-
Neurological deficits: 10–20% (cognitive impairment, seizures, motor deficits).
-
Limb amputation (due to purpura fulminans/DIC): 5–10% of meningococcemia survivors.
-
Renal injury, adrenal hemorrhage (Waterhouse-Friderichsen syndrome).
Prognostic factors: Age <1 year or >60 years, rapid progression, meningococcemia without meningitis, DIC, and coma predict poor outcomes.
Recovery: Survivors without major sequelae typically recover fully within 2–4 weeks.
